Want to join the conversation?
$GILD said the European Commission has granted marketing authorization for Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg), the first pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection. Epclusa was approved by the FDA on June 28 to treat genotype 1-6 chronic HCV infection.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.